This high LOH frequency coincides with mutp53 protein stabilization21, 22 and GOF in human cancers.5, 8 Our TP53 LOH data are in agreement with earlier reports finding 60% TP53 LOH in LFS patients,23 81% in sporadic breast cancer patients (all molecular subtypes pooled)20 and 93% across 10 sporadic human cancer types,24 all expressing missense mutp53. The gene discussed is TP53; the disease is breast carcinoma.